Investigators at NewYork-Presbyterian Hospital conduct and participate in basic science and clinical research to evaluate new therapies for epilepsy. They have played a significant role in the development and assessment of most of the new antiseizure mediations available today, and continue to conduct clinical trials to support new drug development.

For patients with intractable seizures, clinical trials of innovative antiseizure agents are available at both of our Comprehensive Epilepsy Centers. NewYork-Presbyterian investigators are also:

  • Evaluating the effectiveness of new molecular therapies
  • Studying the effects of antiseizure drugs during pregnancy
  • Assessing the effects of antiseizure drugs on bone health
  • Exploring the influence of seizures on learning and memory
  • Evaluating the use of "neuromodulation" devices to treat epilepsy, such as deep brain stimulation and the use of a pacemaker-like device implanted in the skull to short-circuit an oncoming seizure.